Computational drug repurposing aims at finding new medical uses for existing drugs. The identification of novel drug-target interactions (DTIs) can be a useful part of such a task. Computational determination of DTIs is a convenient strategy for systematic screening of a large number of drugs in the attempt to identify new DTIs at low cost and with reasonable accuracy. This necessitates development of accurate computational methods that can help focus on the follow-up experimental validation on a smaller number of highly likely targets for a drug. Although many methods have been proposed for computational DTI prediction, they suffer the high false positive prediction rate or they do not predict the effect that drugs exert on targets in DTIs. In this report, first, we present a comprehensive review of the recent progress in the field of DTI prediction from data-centric and algorithm-centric perspectives. The aim is to provide a comprehensive review of computational methods for identifying DTIs, which could help in constructing more reliable methods. Then, we present DDR, an efficient method to predict the existence of DTIs. DDR achieves significantly more accurate results compared to the other state-of-theart methods. As supported by independent evidences, we verified as correct 22 out of the top 25 DDR DTIs predictions. This validation proves the practical utility of DDR, suggesting that DDR can be used as an efficient method to identify 5 correct DTIs. Finally, we present DDR-FE method that predicts the effect types of a drug on its target. On different representative datasets, under various test setups, and using different performance measures, we show that DDR-FE achieves extremely good performance. Using blind test data, we verified as correct 2,300 out of 3,076 DTIs effects predicted by DDR-FE. This suggests that DDR-FE can be used as an efficient method to identify correct effects of a drug on its target.

Indiana University-Purdue University Indianapolis (IUPUI) / Network-based modeling and analysis have been widely used for capturing molecular trajectories of cellular processes. For complex diseases like cancers, if we can utilize network models to capture adequate features, we can gain a better insight of the mechanism of cancers, which will further facilitate the identification of molecular vulnerabilities and the development targeted therapy. Based on this rationale, we conducted the following four studies: A novel algorithm ‘FFBN’ is developed for reconstructing directional regulatory networks (DEGs) from tissue expression data to identify molecular features. ‘FFBN’ shows unique capability of fast and accurately reconstructing genome-wide DEGs compared to existing methods. FFBN is further used to capture molecular features among liver metastasis, primary liver cancers and primary colon cancers. Comparisons among these features lead to new understandings of how liver metastasis is similar to its primary and distant cancers. ‘SCN’ is a novel algorithm that incorporates multiple types of omics data to reconstruct functional networks for not only revealing molecular vulnerabilities but also predicting drug targets on top of that. The molecular vulnerabilities are discovered via tissue-specific networks and drug targets are predicted via cell-line specific networks. SCN is tested on primary pancreatic cancers and the predictions coincide with current treatment plans. ‘SCN website’ is a web application of ‘SCN’ algorithm. It allows users to easily submit their own data and get predictions online. Meanwhile the predictions are displayed along with network graphs and survival curves. ‘DSCN’ is a novel algorithm derived from ‘SCN’. Instead of predicting single targets like ‘SCN’, ‘DSCN’ applies a novel approach for predicting target combinations using multiple omics data and network models. In conclusion, our studies revealed how genes regulate each other in the form of networks and how these networks can be used for unveiling cancer-related biological processes. Our algorithms and website facilitate capturing molecular features for cancers and predicting novel drug targets.

An important role of Pin1 is to catalyze the cis-trans isomerization of pSer/Thr-Pro bonds; as such, it plays an important role in many cellular events through the effects of conformational change on the function of its biological substrates, including Cdc25, c-Jun, and p53. The expression of Pin1 correlates with cyclin D1 levels, which contributes to cancer cell transformation. Overexpression of Pin1 promotes tumor growth, while its inhibition causes tumor cell apoptosis. Because Pin1 is overexpressed in many human cancer tissues, including breast, prostate, and lung cancer tissues, it plays an important role in oncogenesis, making its study vital for the development of anti-cancer agents. Many inhibitors have been discovered for Pin1, including 1) several classes of designed inhibitors such as alkene isosteres, non-peptidic, small molecular Pin1 inhibitors, and indanyl ketones, and 2) several natural products such as juglone, pepticinnamin E analogues, PiB and its derivatives obtained from a library screen. These Pin1 inhibitors show promise in the development of novel diagnostic and therapeutic anticancer drugs due to their ability to block cell cycle progression. In order to develop potent Pin1 inhibitors, the concept of transition-state analogues was used for the design of three classes of compounds: ketoamide, ketone, and reduced amide analogues. Specifically, a convergent synthesis of α-ketoamide inhibitors of Pin1 was developed. An α-hydroxyorthothioester derivative of Ser was reacted directly with an aminyl synthon. The reaction was catalyzed by HgO and HgCl2 to form an α-hydroxyamide. Hydrolysis and coupling were combined in one step in 80% yield. Two diastereomers of a phospho-Ser-Pro α-ketoamide analogue were synthesized. The resulting IC50 values of 100 µM and 200 µM were surprisingly weak for the Pin1 peptidyl-prolyl isomerase. Diastereomeric ketones were synthesized by coupling cyclohexenyl lithium to the serine Weinreb amide, via the Michael addition of a carboxylate synthon. The IC50 values of the two ketone diastereomers were determined to be 260 μM and 61 μM, respectively. Five reduced amide inhibitors for Pin1 were synthesized through a selective reduction using borane. The most potent inhibitor was found to be Fmocâ pSerâ Ψ[CH2N]-Proâ tryptamine, which had an IC50 value of 6.3 µM. This represents a 4.5-fold better inhibition for Pin1 than a comparable cis-amide alkene isostere. The co-crystal structure of Acâ pSerâ Ψ[CH2N]-Proâ tryptamine bound to Pin1 was determined to 1.76 Ã resolution. Towards understanding the two proposed mechanisms of Pin1 catalysis, nucleophilic-additition mechanism and twisted-amide mechanism, three classes of Pin1 inhibitors (ketoamide, ketone, and reduced amide analogues) involving a total of nine compounds were synthesized and evaluated. The weak inhibitory activities of ketoamide and ketone analogues do not support the nucleophilic-addition mechanism, while the twisted-amide mechanism of Pin1 catalysis is promising based on the reduced amide inhibitors with good potencies. / Ph. D.

Most known drug targets and metabolizing enzymes are located inside cells. Interactions with these proteins are determined by intracellular unbound drug concentrations. Assessing intracellular drug exposure is technically challenging, but essential for predicting pharmacokinetic, pharmacological, and toxicological profiles of new drugs. This thesis aims at establishing and applying a straightforward methodology to measure intracellular unbound drug concentrations. This was achieved by separately measuring cellular drug binding (fu,cell), and total intracellular drug accumulation (Kp). This allowed the calculation of intracellular drug bioavailability (Fic), which represents the fraction of the concentration added to the cells that is unbound in the cell interior. The methodology was initially developed in HEK293 cells, where the Fic of 189 drug-like compounds was measured. Binding to HEK293 cells was governed by compound lipophilicity and was correlated with binding to more complex systems, such as hepatocytes and brain. Due to negligible expression of drug transporters, Fic in this cell line was consistent with pH-dependent subcellular sequestration of lipophilic cations in low pH compartments. The methodology was then applied to study the effects of drug transporters on Fic. The uptake transporter OATP1B1 increased the Fic of its substrates in a concentration-dependent manner. In contrast, the Fic of P-gp substrates was decreased when P-gp was present. In human hepatocytes, the methodology allowed the determination of Fic without prior knowledge of transporter mechanisms or metabolic activity. Finally, the methodology was applied to measure the impact of Fic on target binding and cellular drug response. Intracellular concentrations of active metabolites of pro-drugs targeting the intracellular target thymidylate synthase were in agreement with the level of binding to this target. Further, high Fic was generally required for kinase and protease inhibitors to be active in cellular assays. In conclusion, the methodology can be used to predict if new drug candidates reach their intracellular targets in sufficient amounts. Furthermore, the methodology can improve in vitro predictions of drug clearance and drug-drug interactions, by measuring the drug available for intracellular enzymes. Finally, this work can be expanded to other xenobiotics, e.g., to predict their intracellular toxicity.

Thesis (PhD)--Stellenbosch University, 2013. / ENGLISH ABSTRACT: Malaria infects over 200 million individuals and leads to the death of over 600 000 people annually. Currently artemisinin combination therapy treatments are effective in treating the disease, but resistance has started to emerge in Cambodia and it is suspected in parts of Vietnam. To maintain the drive to eradicate malaria globally, a great deal of research is aimed at identifying novel prevention strategies, vaccines and antimalarial compounds. Plasmodium falciparum, the most deadly of the malaria parasites, is entirely dependent on glycolysis for ATP. Several of the enzymes within this pathway have been proposed as drug targets and studied in isolation, but the pathway as a whole has not been considered. In this study we employ a bottom up approach for drug target identification in P. falciparum glycolysis. In this thesis we present the biochemical characterisation each of the glycolytic enzymes in P. falciparum trophozoites. The kinetic rate equations, which described the kinetic behaviour of the individual enzymes, were incorporated into a kinetic model. The unfitted model was validated in its ability to predict experimentally measured steady state metabolite concentrations and fluxes as well as the experimental inhibition of the glucose transporter. The validated model provided a tool for drug target identification in P. falciparum glycolysis. Metabolic control analysis and differential control analysis identified the glucose transporter, PfHT1, as a drug target based on its high control of glycolytic flux in the parasite, but low control of flux in the host erythrocyte. This differential control makes the transporter an attractive drug target, as even if both the erythrocyte and parasite glucose transporters are inhibited to the same degree, it is expected that the parasite glycolytic flux would be inhibited to a much greater degree. To demonstrate the differential control of the glucose transporter on the flux and provide further evidence that PfHT1 is an attractive drug target, we investigated the inhibition of the glucose transporter in isolated trophozoites by cytochalasin B. We also measured the inhibition of lactate production flux by cytochalasin B in both isolated P. falciparum trophozoites as well as in erythrocytes. Our findings demonstrated that differential control analysis can be used as a tool for drug target identification and that PfHT1 is an attractive drug target. In this study the fields of biochemistry and systems biology were merged to create a detailed kinetic model of asexual P. falciparum glycolysis and identify several drug targets in the pathway. The model prediction and experimental evidence of differential flux control of the glucose transporter in the host and parasite, has highlighted PfHT1 as a drug target and also demonstrates the strength of differential control analysis in identifying drug targets within a system. The kinetic model is a valuable tool for furthering our understanding of P. falciparum glycolysis and it provides a good foundation for expansion to identify drug targets in the entire central carbon metabolism of P. falciparum. / AFRIKAANSE OPSOMMING: Malaria infekteer meer as 200 miljoen mense en veroorsaak jaarliks tot 600 000 sterftes. Tans is die artemisinien-kombinasieterapie effektief in die bestryding van die siekte, maar weerstandbiedendheid van die parasiet teen die middel blyk reeds ’n merkbare effek in Kambodja en vermoedelik ook in dele van Viëtnam te hê. Om ’n wêreldwye bestryding van malaria moontlik te maak, is ’n groot deel van die huidige navorsing gemik op die identifisering van nuwe voorkomingsstrategieë, entstowwe en malariateenmiddels. Plasmodium falciparum, die dodelikste van die malaria-parasiete, is geheel en al afhanklik van glikolise vir ATP vorming. Verskeie van die ensieme in hierdie metaboliese pad is as teenmiddelteikens voorgestel, en in isolasie bestudeer, maar die pad as ’n geheel is nie bestudeer nie. In hierdie studie het ons ’n ’bottom-up’ benadering vir teenmiddel teikenidentifisering in P. falciparum glikolise gebruik. In hierdie tesis bied ons die biochemiese karakterisering van elk van die glikolitiese ensieme in P. falciparum trofozoïete aan. Die kinetiese vergelykings wat die kinetiese gedrag van die individuele ensieme beskryf, is geintegreer in ’n enkele kinetiese model. Die model waarop geen datapassing toegepas is nie, is gevalideer om eksperimenteel bepaalde bestendige-toestand metabolietkonsentrasies en fluksiewaardes, asook die eksperimentele inhibisie van die glukose transporter, te voorspel. Die gevalideerde model verskaf ’n bykomende hulpmiddel om teenmiddelteikens te identifiseer in P. falciparum glikolise. Metaboliese kontrole-analise en differensiële kontrole-analise het die glukose transporter, PfHT1, as ’n teenmiddelteiken geïdentifiseer, gebaseer op sy hoë kontrole van glikolitiese fluksie in die parasiet, tesame met ’n lae beheer van die glukose transporter op die fluksie in die gasheer eritrosiet. Dié differensiële kontrole maak die glukose transporter ’n aantreklike teenmiddelteiken, want selfs as beide die eritrosiet en die parasiet glukose transporters tot dieselfde mate geïnhibeer word, sal dit steeds ’n hoër glikolietiese fluksieinhibisie van die parasiet tot gevolg hê. Om die differensiële kontrole van die glukose transporter op die fluks te demonstreer en verdere bewyse te lewer dat PfHT1 ’n teenmiddelteiken kan wees, het ons die inhibisie van die glukosetransporter in geïsoleerde trofozoïete deur sitokalasien B ondersoek. Ons het ook die inhibisie van die laktaatproduksiefluksie deur sitokalasien B in beide geïsoleerde P. falciparum trofozoïete sowel as in eritrosiete ondersoek. Ons bevindings bewys dat differensiële kontroleanalise as ’n hulpmiddel vir teenmiddelteikenidentifikasie gebruik kan word en dat PfHT1 ’n aantreklike teenmiddelteiken is. In hierdie studie is die velde van biochemie en sisteembiologie gekombineer om ’n gedetaileerde kinetiese model van ongeslagtelike P. falciparum glikolise te konstueer en verskeie teenmiddelteikens in die metaboliese pad te identifiseer. Die modelvoorspelling sowel as eksperimentele bewyse van die differensiële flukskontrole van die glukose transporter in die gasheer en parasiet het PfHT1 uitgelig as ’n teenmiddelteiken en demonstreer ook die krag van differensiële kontrole analise in die identifisering van teenmiddelteikens binne ’n biologiese stelsel. Die kinetiese model is ’n waardevolle hulpmiddel vir die bevordering van ons begrip van P. falciparum glikolise en dit bied ’n goeie basis vir uitbreiding om teenmiddelteikens in die hele sentrale koolstofmetabolisme van P. falciparum te identifiseer.

No description available.

Mycobacterium abscessus est une mycobactérie à croissance rapide qui a récemment émergé en tant que pathogène opportuniste, en particulier chez les patients atteints de mucoviscidose. Elle est naturellement résistante aux antibiotiques les plus couramment disponibles, limitant sérieusement les options thérapeutiques chez les patients infectés. Il apparaît donc urgent d’identifier et de caractériser de nouvelles cibles d’intérêt thérapeutique dans la lutte contre ce pathogène. Contrairement au variant lisse (S) de M. abscessus, caractérisé par une forte production de glycopeptidolipides (GPL), le variant rugueux (R) associé à une faible production de GPL est responsable des manifestations cliniques les plus sévères. Chez l’embryon de poisson zèbre, le variant R s’accompagne d’une virulence accrue avec formation de cordes mycobactériennes extracellulaires et d’abcès, engendrant une mortalité rapide des larves infectées. Les mécanismes moléculaires de la pathogénicité de M. abscessus demeurent toutefois très peu connus.Dans cette étude, nous avons identifié le gène MAB_4780, codant une déshydratase distincte du complexe HadABC impliqué dans la biosynthèse des acides mycoliques. Le gène MAB_4780, tout comme son homologue chez M. smegmatis, MSMEG_6754, ont été identifiés comme responsables de la résistance innée de ces deux espèces au thiacetazone (TAC), un agent antituberculeux de seconde intention. Nous avons inactivé le gène MAB_4780 dans le variant R de M. abscessus, ce qui a entraîné une modification de la composition en acides mycoliques, un défaut de formation des cordes mycobactériennes ainsi qu'un phénotype extrêmement atténué chez les embryons de poisson zèbre. L'atténuation in vivo du mutant MAB_4780 qui résulte très vraisemblablement de l’incapacité i) à former des cordes et ii) à inhiber la fusion phagolysosomale, s’accompagne d’une croissance intracellulaire diminuée. En outre, le mutant MAB_4780, tout comme le mutant de M. smegmatis dépourvu de MSMEG_6754, présente une croissance altérée dans l’amibe, qui représente un réservoir pour les mycobactéries environnementales. Ces résultats reflètent le rôle crucial de cette nouvelle déshydratase dans la survie de M. abscessus dans son environnement et dans l'établissement d'infections aiguës et létales. Par conséquent, cibler MAB_4780 pourrait représenter une stratégie particulièrement prometteuse pour contrôler les infections à M. abscessus. De futures études seront consacrées à l'identification d’inhibiteurs spécifiques de MAB_4780, grâce au développement d’un test d’activité et d’une structure cristalline de la protéine obtenue à très haute résolution.Nous avons également criblé contre M. abscessus une chimiothèque d’analogues structuraux du TAC, préalablement validés pour leur activité inhibitrice de la déshydratase HadABC de Mycobacterium tuberculosis. Trois d’entre eux ont montré une efficacité accrue d’un facteur 50 par rapport à la molécule parentale. La surexpression d’EthA, l’activateur du TAC, augmente la susceptibilité de M. abscessus à ces trois analogues. Ces résultats suggèrent que leur mode d'activation est similaire à celle de la TAC et indiquent que l'optimisation d’analogues du TAC pourrait conduire à une nouvelle génération de composés plus efficaces pour le traitement de M. abscessus. Des études de relations structure/activité sont envisagées afin d’améliorer l’efficacité et les propriétés pharmacologiques des analogues du TAC. / Mycobacterium abscessus, a rapidly-growing mycobacterium (RGM), has emerged in recent years as an important opportunistic pathogen especially in cystic fibrosis (CF) patients. M. abscessus is naturally resistant to most commonly available antibiotics, which seriously limits the treatment options, emphasizing the urgent need for more efficient drugs and innovative therapeutic strategies to combat M. abscessus infections. The M. abscessus rough (R) low-glycopeptidolipids (GPL) producer is responsible for more severe clinical infections than the smooth (S) high-GPL producer, and is associated with increased virulence in zebrafish, including the formation of massive serpentine cords, abscesses, and rapid larval death. However, the molecular mechanisms responsible for the pathogenicity of the R strains remain elusive.Herein, we identified a novel gene, MAB_4780, encoding a dehydratase distinct from the HadABC complex, known to participate in mycolic acid biosynthesis. Both MAB_4780 and its homologue in Mycobacterium smegmatis, MSMEG_6754, are responsible for the innate resistance in these species to thiacetazone (TAC), a second-line antitubercular drug. The successful deletion of MABS_4780 in the R variant of M. abscessus resulted in an altered mycolic acid composition, a pronounced defect in cording, and an extremely attenuated phenotype in zebrafish embryos. The in vivo attenuation of the MAB_4780 mutant results from both the deficiency in cord formation and the impaired intracellular growth, presumably due to limited inhibition of the phagolysosomal fusion events. In addition, similarly to the MSMEG_6754 deletion mutant, the MAB_4780 mutant showed impaired growth in amoeba, which represents a possible reservoir for environmental mycobacteria. These results reflect the critical role of this new dehydratase in the survival of M. abscessus in its environmental hosts and its importance in establishing acute and lethal infections. Therefore, targeting MAB_4780 may represent a promising strategy to control M. abscessus infections. Future work will focus on identifying specific inhibitors targeting MAB_4780, which could greatly benefit from the combination of our dehydratase assay and our high-resolution crystal structure of the protein.We have also screened against M. abscessus a library of TAC analogues, previously validated for their inhibitory effects against the Mycobacterium tuberculosis HadABC dehydratase. Among these compounds, three exhibited a 50-fold increased potency as compared to TAC. Overexpression of EthA, known as the activator of TAC, increased the susceptibility of M. abscesuss to the three analogues, suggesting that that their mode of activation is similar to that of TAC. Overall, these data indicate that optimizing the TAC scaffold may lead to more efficient compounds against M. abscessus. Additional structure/activity relationship studies are required to further improve the efficacy and pharmacological properties of TAC analogues.

The amount of biomedical literature has been increasing rapidly during the last decade. Text mining techniques can harness this large-scale data, shed light onto complex drug mechanisms, and extract relation information that can support computational polypharmacology. In this work, we introduce CASSANDRA, a fully corpus-based and unsupervised algorithm which uses the MEDLINE indexed titles and abstracts to infer drug gene associations and assist drug repositioning. CASSANDRA measures the Pointwise Mutual Information (PMI) between biomedical terms derived from Gene Ontology (GO) and Medical Subject Headings (MeSH). Based on the PMI scores, drug and gene profiles are generated and candidate drug gene associations are inferred when computing the relatedness of their profiles. Results show that an Area Under the Curve (AUC) of up to 0.88 can be achieved. The algorithm can successfully identify direct drug gene associations with high precision and prioritize them over indirect drug gene associations. Validation shows that the statistically derived profiles from literature perform as good as (and at times better than) the manually curated profiles. In addition, we examine CASSANDRA’s potential towards drug repositioning. For all FDA-approved drugs repositioned over the last 5 years, we generate profiles from publications before 2009 and show that the new indications rank high in these profiles. In summary, co-occurrence based profiles derived from the biomedical literature can accurately predict drug gene associations and provide insights onto potential repositioning cases.

RNAs have become increasingly recognized as possible drug targets due to their involvement in important biochemical functions, as well as their unique but well-defined structures. Recently published crystal structures depict the binding of a series of aminoglycosides- or more specifically- 2-deoxystretamine (2-DOS), the most preserved central scaffold of aminoglycosides, to a conserved 5'-GU-3'region on their target RNAs. A novel unnatural γ-amino acid, 1, has been synthesized using 2-deoxystreptamine as a template through structure-based rational design. The unnatural amino acid has been designed to replace a glycosidic linkage with an amide bond, which may limit the promiscuous binding characteristics of aminoglycosides through increased rigidity of the ligands and additional hydrogen bonding. The binding selectivity and affinity will be studied in the future through a fluorescence assay.

No description available.